Literature DB >> 12839944

Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.

Satoshi Kiyama1, Kevin Morrison, Tobias Zellweger, Majid Akbari, Michael Cox, Duan Yu, Hideaki Miyake, Martin E Gleave.   

Abstract

Activation of alternative growth factor pathways after androgen withdrawal is one mechanism mediating androgen-independent (AI) progression in advanced prostate cancer. Insulin-like growth factor (IGF) I activation is modulated by a family of IGF binding proteins (IGFBPs). Although IGFBP-2 is one of the most commonly overexpressed genes in hormone refractory prostate cancer, the functional significance of changes in IGF-I signaling during AI progression remains poorly defined. In this article, we characterize changes in IGFBP-2 in the LNCaP tumor model after androgen withdrawal and evaluate its functional significance in AI progression using gain-of-function and loss-of-function analyses. IGFBP-2 mRNA and protein levels increase 2-3-fold after androgen withdrawal in LNCaP cells in vitro in LNCaP tumors during AI progression in vivo. Increased IGFBP-2 levels after castration were also identified using a human prostate tissue microarray of untreated and posthormone therapy-treated prostatectomy specimens. LNCaP cell transfectants that stably overexpressed IGFBP-2 progressed more rapidly after castration than control tumors. Antisense oligonucleotides (ASOs) targeting the translation initiation site of IGFBP-2 reduced IGFBP-2 mRNA and protein expression by >70% in a dose-dependent and sequence-specific manner. ASO-induced decreases in IGFBP-2-reduced LNCaP cell growth rates and increased apoptosis 3-fold. LNCaP tumor growth and serum prostate-specific antigen levels in mice treated with castration plus adjuvant IGFBP-2 ASOs were significantly reduced compared with mismatch control oligonucleotides. Increased IGFBP-2 levels after androgen ablation may represent an adaptive response that helps potentiate IGF-I-mediated survival and mitogenesis and promote androgen-independent tumor growth. Inhibiting IGFBP-2 expression using ASO technology may offer a treatment strategy to delay AI progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839944

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

2.  Androgen mediated translational and postranslational regulation of IGFBP-2 in androgen-sensitive LNCaP human prostate cancer cells.

Authors:  David J Degraff; Adam A Aguiar; Qian Chen; Lisa K Adams; B Jill Williams; Robert A Sikes
Journal:  Am J Transl Res       Date:  2010-03-06       Impact factor: 4.060

Review 3.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin Gleave; Hideaki Miyake
Journal:  World J Urol       Date:  2005-01-26       Impact factor: 4.226

Review 4.  Mechanisms of the development of androgen independence in prostate cancer.

Authors:  Alan So; Martin Gleave; Antonio Hurtado-Col; Colleen Nelson
Journal:  World J Urol       Date:  2005-01-27       Impact factor: 4.226

5.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

Authors:  Shen Gao; Peng Lee; Hua Wang; William Gerald; Michael Adler; Liying Zhang; Yun-Fang Wang; Zhengxin Wang
Journal:  Mol Endocrinol       Date:  2005-02-24

6.  Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD.

Authors:  Amina Zoubeidi; Anousheh Zardan; Romina M Wiedmann; Jennifer Locke; Eliana Beraldi; Ladan Fazli; Martin E Gleave
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

7.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

8.  PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.

Authors:  Kenichi Miyako; Laura J Cobb; Malik Francis; Alden Huang; Bonnie Peng; John E Pintar; Hiroyoshi Ariga; Pinchas Cohen
Journal:  Mol Endocrinol       Date:  2008-12-18

9.  Population-dependent Intron Retention and DNA Methylation in Breast Cancer.

Authors:  Dongwook Kim; Manu Shivakumar; Seonggyun Han; Michael S Sinclair; Young-Ji Lee; Yonglan Zheng; Olufunmilayo I Olopade; Dokyoon Kim; Younghee Lee
Journal:  Mol Cancer Res       Date:  2018-01-12       Impact factor: 5.852

10.  Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors:  T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.